Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Minimal residual disease-negativity after treatment in DLBCL strongly correlates with remission and overall survival. However ...

In the phase 3 PANOVA-3 trial, patients who underwent tumor-treating fields therapy had extended overall survival vs standard ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of May, spanning various cancer types.

ROANOKE COUNTY, Va. (WDBJ) - Roanoke County Public Schools officials say they feel the district is not responsible for the ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical ...

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

Rina-S led to a 50% response rate, including two complete responses, in heavily pretreated advanced endometrial cancer, ...

INB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated ...

The company’s global head of human performance and an eminent psychophysiologist, Dr Holmes studies the link between ...

With high energy prices and supply chain disruptions creating shortages of renewable energy components and materials, emerging markets are reassessing how to build out utility-scale solar power to ...

Novartis is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety of Kisqali(R) (ribociclib) plus endocrine therapy (ET, a non-steroidal ...